OverviewChartTechnicalNewsTraderScreen

Corcept Therapeutics Inc/  US2183521028  /

NASDAQ
2024-04-18  6:18:24 PM Chg. +0.2150 Volume Bid6:19:01 PM Ask6:19:01 PM High Low
23.2150USD +0.93% 255,857
Turnover: 4.75 mill.		 23.2000Bid Size: 300 23.2500Ask Size: 200 23.4400 22.6900
GlobeNewswire 04-15 Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis ...
GlobeNewswire 04-08 Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Plati...
GlobeNewswire 04-01 Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cush...
GlobeNewswire 03-06 Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
GlobeNewswire 02-15 Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provi...
GlobeNewswire 02-15 Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
GlobeNewswire 02-08 Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corpor...
GlobeNewswire 02-08 BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
GlobeNewswire 01-29 Corcept Appoints Roberto Vieira as President, Oncology
GlobeNewswire 01-08 Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
GlobeNewswire 01-02 Court Finds Corcept Therapeutics’ Patents Not Infringed
GlobeNewswire 2023-12-04 Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
GlobeNewswire 2023-11-01 Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
GlobeNewswire 2023-11-01 Corcept Appoints Monica Tellado as President, Emerging Markets
GlobeNewswire 2023-10-26 Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)
GlobeNewswire 2023-10-25 Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host ...
GlobeNewswire 2023-09-11 eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors
GlobeNewswire 2022-03-26 Bragar Eagel & Squire, P.C. Is Investigating Corcept, Verra, Core Scientific, and Applied Therapeuti...
GlobeNewswire 2022-03-21 Bragar Eagel & Squire, P.C. Is Investigating Porch, Virgin Galactic, Corcept, and Verra and Encourag...
GlobeNewswire 2022-03-15 Bragar Eagel & Squire, P.C. Is Investigating Verra, Corcept, Core Scientific, and Applied Therapeuti...
GlobeNewswire 2022-03-10 Bragar Eagel & Squire, P.C. Is Investigating Corcept, Medallion, Clariant, and Anavex and Encourages...
GlobeNewswire 2022-03-05 Bragar Eagel & Squire, P.C. Is Investigating CareDx, Medallion, Corcept, and Clariant and Encourages...
GlobeNewswire 2022-03-01 Corcept Therapeutics to Host Ovarian Cancer Program Update on Thursday, March 31, 2022
GlobeNewswire 2022-02-28 Bragar Eagel & Squire, P.C. Is Investigating Agrify, CareDx, Inc., Medallion Financial, and Corcept ...
GlobeNewswire 2022-02-22 Bragar Eagel & Squire, P.C. Is Investigating Agrify, CareDx, Medallion, and Corcept and Encourages I...